Leptin Signals Via TGFB1 to Promote Metastatic Potential and Stemness in Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 May 26

PMID 28542577

Citations 35

Authors

Ameet K Mishra

Christopher R Parish

Ma-Li Wong

Julio Licinio

Anneke C Blackburn

Affiliations

Soon will be listed here.

Abstract

Epidemiological studies have shown obesity to be linked with poorer outcomes in breast cancer patients. The molecular mechanisms responsible for the increased risk of invasive/metastatic disease with obesity are complex, but may include elevated levels of adipokines such as leptin. Using physiological levels of leptin found in obesity in a novel chronic in vitro treatment model (≤200 ng/ml for 14 days), we confirmed the occurrence of leptin-mediated changes in growth, apoptosis and metastatic behavior, and gene expression changes representing epithelial-to-mesenchymal transition (EMT) and a cancer stem cell (CSC) like phenotype in breast epithelial and cancer cell lines (MCF10A, MCF10AT1, MCF7 and MDA-MB-231). Further, we have discovered that these effects were accompanied by increased expression of TGFB1, and could be significantly reduced by co-treatment with neutralizing antibody against TGFB1, indicating that the induction of these characteristics was mediated via TGFB1. Occurring in both MCF7 and MCF10AT1 cells, it suggests these actions of leptin to be independent of estrogen receptor status. By linking leptin signalling to the established TGFB1 pathway of metastasis / EMT, this study gives a direct mechanism by which leptin can contribute to the poorer outcomes of obese cancer patients. Inhibitors of TGFB1 are in currently in phase III clinical trials in other malignancies, thus identifying the connection between leptin and TGFB1 will open new therapeutic opportunities for improving outcomes for obese breast cancer patients.

Citing Articles

Regulation of mitochondrial metabolism by autophagy supports leptin-induced cell migration.

Garcia-Miranda A, Montes-Alvarado J, Sarmiento-Salinas F, Vallejo-Ruiz V, Castaneda-Saucedo E, Navarro-Tito N Sci Rep. 2024; 14(1):1408.

PMID: 38228661 PMC: 10791685. DOI: 10.1038/s41598-024-51406-y.

Role of Leptin and Adiponectin in Carcinogenesis.

Bocian-Jastrzebska A, Malczewska-Herman A, Kos-Kudla B Cancers (Basel). 2023; 15(17).

PMID: 37686525 PMC: 10486522. DOI: 10.3390/cancers15174250.

Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications.

Ordaz-Ramos A, Tellez-Jimenez O, Vazquez-Santillan K Front Cell Dev Biol. 2023; 11:1221175.

PMID: 37492224 PMC: 10363614. DOI: 10.3389/fcell.2023.1221175.

Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation.

Zhang H, Wang M, Xu Y Cancer Biol Med. 2023; 20(4).

PMID: 36880535 PMC: 10157808. DOI: 10.20892/j.issn.2095-3941.2022.0547.

Adipokines and epithelial-mesenchymal transition (EMT) in cancer.

Akrida I, Papadaki H Mol Cell Biochem. 2023; 478(11):2419-2433.

PMID: 36715963 DOI: 10.1007/s11010-023-04670-x.

References

Dignam J, Mamounas E . Obesity and breast cancer prognosis: an expanding body of evidence. Ann Oncol. 2004; 15(6):850-1. DOI: 10.1093/annonc/mdh241. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Xie M, Zhang D, Dyck J, Li Y, Zhang H, Morishima M . A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A. 2006; 103(46):17378-83. PMC: 1859937. DOI: 10.1073/pnas.0604708103. View

Garofalo C, Surmacz E . Leptin and cancer. J Cell Physiol. 2005; 207(1):12-22. DOI: 10.1002/jcp.20472. View

Haakinson D, Leeds S, Dueck A, Gray R, Wasif N, Stucky C . The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012; 19(9):3012-8. DOI: 10.1245/s10434-012-2320-8. View

Ghiasvand R, Bahmanyar S, Zendehdel K, Tahmasebi S, Talei A, Adami H . Postmenopausal breast cancer in Iran; risk factors and their population attributable fractions. BMC Cancer. 2012; 12:414. PMC: 3517420. DOI: 10.1186/1471-2407-12-414. View

Karaduman M, Bilici A, Ozet A, Sengul A, Musabak U, Alomeroglu M . Tissue leptin levels in patients with breast cancer. J BUON. 2010; 15(2):369-72. View

Liu R, Zeng Y, Lei Z, Wang L, Yang H, Liu Z . JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol. 2014; 44(5):1643-51. DOI: 10.3892/ijo.2014.2310. View

Smith A, Robin T, Ford H . Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res. 2012; 18(17):4514-21. DOI: 10.1158/1078-0432.CCR-11-3224. View

10.

Binai N, Damert A, Carra G, Steckelbroeck S, Lower J, Lower R . Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer. 2009; 127(1):55-66. DOI: 10.1002/ijc.25010. View

11.

Wu M, Chou Y, Chou W, Hsu G, Chu C, Yu C . Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009; 100(4):578-82. PMC: 2653731. DOI: 10.1038/sj.bjc.6604913. View

12.

Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W . Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014; 5:e1088. PMC: 3944271. DOI: 10.1038/cddis.2014.59. View

13.

Wolf G, Hamann A, Han D, Helmchen U, Thaiss F, Ziyadeh F . Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]. Kidney Int. 1999; 56(3):860-72. DOI: 10.1046/j.1523-1755.1999.00626.x. View

14.

Glueck C, Fontaine R, Wang P, Subbiah M, Weber K, Illig E . Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001; 50(7):856-61. DOI: 10.1053/meta.2001.24192. View

15.

Maor G, Rochwerger M, Segev Y, Phillip M . Leptin acts as a growth factor on the chondrocytes of skeletal growth centers. J Bone Miner Res. 2002; 17(6):1034-43. DOI: 10.1359/jbmr.2002.17.6.1034. View

16.

McNee R, Mason B, Neave L, Kay R . Influence of height, weight, and obesity on breast cancer incidence and recurrence in Auckland, New Zealand. Breast Cancer Res Treat. 1987; 9(2):145-50. DOI: 10.1007/BF01807367. View

17.

Harvie M, Hooper L, Howell A . Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003; 4(3):157-73. DOI: 10.1046/j.1467-789x.2003.00108.x. View

18.

Feng H, Liu Q, Zhang N, Zheng L, Sang M, Feng J . Leptin promotes metastasis by inducing an epithelial-mesenchymal transition in A549 lung cancer cells. Oncol Res. 2014; 21(3):165-71. DOI: 10.3727/096504014X13887748696662. View

19.

Yan D, Avtanski D, Saxena N, Sharma D . Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem. 2012; 287(11):8598-612. PMC: 3318705. DOI: 10.1074/jbc.M111.322800. View

20.

Rene Gonzalez R, Watters A, Xu Y, Singh U, Mann D, Rueda B . Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009; 11(3):R36. PMC: 2716504. DOI: 10.1186/bcr2321. View